NCT05567822

Brief Summary

The aim of this study will be to investigate the effect of a continuous infusion of low dose esmolol on intraoperative and postoperative opioid consumption, as well as on postoperative recovery and chronic pain

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
70

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Oct 2022

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 1, 2022

Completed
Same day until next milestone

Study Start

First participant enrolled

October 1, 2022

Completed
4 days until next milestone

First Posted

Study publicly available on registry

October 5, 2022

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2024

Completed
Last Updated

October 27, 2022

Status Verified

October 1, 2022

Enrollment Period

2 years

First QC Date

October 1, 2022

Last Update Submit

October 25, 2022

Conditions

Outcome Measures

Primary Outcomes (3)

  • pain score 3 hours postoperatively

    pain score by the use of Numeric Rating Scale (NRS) 3 hours postoperatively, ranging from 0 to 10, where 0 means "no pain" and 10 means "worst pain imaginable"

    3 hours postoperatively

  • pain score 6 hours postoperatively

    pain score by the use of Numeric Rating Scale (NRS) 6 hours postoperatively, ranging from 0 to 10, where 0 means "no pain" and 10 means "worst pain imaginable"

    6 hours postoperatively

  • pain score 24 hours postoperatively

    pain score by the use of Numeric Rating Scale (NRS) 24 hours postoperatively, ranging from 0 to 10, where 0 means "no pain" and 10 means "worst pain imaginable"

    24 hours postoperatively

Other Outcomes (27)

  • pain score on arrival to Post-Anesthesia Care Unit (PACU)

    immediately postoperatively

  • pain score at discharge from Post-Anesthesia Care Unit (PACU)

    at discharge from Post Anesthesia Care Unit (PACU), approximately 1 hour postoperatively]

  • sevoflurane consumption during general anesthesia

    change of sevoflurane vaporizer weight from before induction to end of anesthesia, an average period of 1-2 hours

  • +24 more other outcomes

Study Arms (2)

esmolol group

ACTIVE COMPARATOR

loading dose of esmolol 0.05 mL/kg and maintenance dose of esmolol 0.3 mL/kg/h

Drug: Esmolol Hydrochloride

placebo group

PLACEBO COMPARATOR

loading dose of 0.9% sodium chloride 0.05 mL/kg and maintenance dose of 0.9% sodium chloride 0.3 mL/kg/h

Drug: normal saline

Interventions

In the esmolol group, patients will receive a bolus dose of esmolol followed by a continuous infusion of esmolol intraoperatively

esmolol group

In the placebo group, patients will receive a bolus dose of normal saline followed by a continuous infusion of normal saline intraoperatively

placebo group

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • adult patients
  • American Society of Anesthesiologists (ASA) classification I-II
  • elective inguinal hernia repair

You may not qualify if:

  • body mass index (BMI) \>35 kg/m2
  • β-blocker administration preoperatively
  • systematic use of analgesic agents preoperatively
  • chronic pain syndromes preoperatively
  • neurological or psychiatric disease on treatment
  • pregnancy
  • severe hepatic or renal disease
  • history of cardiovascular diseases/ arrhythmias/ conduction abnormalities
  • hemodynamic instability
  • drug or alcohol abuse
  • language or communication barriers
  • lack of informed consent
  • bilateral inguinal hernia repair

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Evangelismos General Hospital

Athens, 10676, Greece

RECRUITING

Related Publications (6)

  • Egan TD. Are opioids indispensable for general anaesthesia? Br J Anaesth. 2019 Jun;122(6):e127-e135. doi: 10.1016/j.bja.2019.02.018. Epub 2019 Mar 28.

    PMID: 31104756BACKGROUND
  • Salome A, Harkouk H, Fletcher D, Martinez V. Opioid-Free Anesthesia Benefit-Risk Balance: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Clin Med. 2021 May 12;10(10):2069. doi: 10.3390/jcm10102069.

    PMID: 34065937BACKGROUND
  • Bahr MP, Williams BA. Esmolol, Antinociception, and Its Potential Opioid-Sparing Role in Routine Anesthesia Care. Reg Anesth Pain Med. 2018 Nov;43(8):815-818. doi: 10.1097/AAP.0000000000000873.

    PMID: 30216240BACKGROUND
  • Gelineau AM, King MR, Ladha KS, Burns SM, Houle T, Anderson TA. Intraoperative Esmolol as an Adjunct for Perioperative Opioid and Postoperative Pain Reduction: A Systematic Review, Meta-analysis, and Meta-regression. Anesth Analg. 2018 Mar;126(3):1035-1049. doi: 10.1213/ANE.0000000000002469.

    PMID: 29028742BACKGROUND
  • Watts R, Thiruvenkatarajan V, Calvert M, Newcombe G, van Wijk RM. The effect of perioperative esmolol on early postoperative pain: A systematic review and meta-analysis. J Anaesthesiol Clin Pharmacol. 2017 Jan-Mar;33(1):28-39. doi: 10.4103/0970-9185.202182.

    PMID: 28413270BACKGROUND
  • Andresen K, Rosenberg J. Management of chronic pain after hernia repair. J Pain Res. 2018 Apr 5;11:675-681. doi: 10.2147/JPR.S127820. eCollection 2018.

    PMID: 29670394BACKGROUND

MeSH Terms

Conditions

Acute PainPain, PostoperativeAgnosiaNociceptive Pain

Interventions

esmololSaline Solution

Condition Hierarchy (Ancestors)

PainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsPostoperative ComplicationsPathologic ProcessesPerceptual DisordersNeurobehavioral ManifestationsNervous System Diseases

Intervention Hierarchy (Ancestors)

Crystalloid SolutionsIsotonic SolutionsSolutionsPharmaceutical Preparations

Central Study Contacts

Kassiani Theodoraki, PhD, DESA

CONTACT

Vasiliki Samartzi

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor of Anesthesiology

Study Record Dates

First Submitted

October 1, 2022

First Posted

October 5, 2022

Study Start

October 1, 2022

Primary Completion

October 1, 2024

Study Completion

October 1, 2024

Last Updated

October 27, 2022

Record last verified: 2022-10

Data Sharing

IPD Sharing
Will not share

Locations